AgomAb Therapeutics Raises $200 Million in IPO for Fibrotic Disorder Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy AGMB?
Source: renaissancecapital
- Funding Achievement: AgomAb Therapeutics successfully raised $200 million by offering 12.5 million shares at $16 each, priced at the midpoint of the $15 to $17 range, indicating strong market demand for its innovative therapies.
- Market Valuation: Following this financing, AgomAb commands a fully diluted market value of $875 million, reflecting investor confidence in its potential within the chronic fibrotic disease market, particularly given the high unmet medical needs.
- Product Pipeline: The lead product candidate, ontunisertib (AGMB-129), is a selective oral small molecule inhibitor targeting Fibrostenosing Crohn’s Disease, showcasing promising clinical prospects and potentially offering new treatment options for patients.
- Future Plans: The company plans to list on Nasdaq under the ticker AGMB, which is expected to enhance its market visibility and provide funding for further research and market development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGMB
Wall Street analysts forecast AGMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGMB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 0.000
Low
Averages
High
Current: 0.000
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
